实验性肝纤维化大鼠脂联素及其受体2的表达被引量：1

Study on expression of adiponectin and its receptor 2 in rats with experimental liver fibrosis

下载PDF

导出

摘要目的探讨血清脂联素蛋白(APN)及肝脏脂联素受体2 mRNA的表达在实验性大鼠肝纤维化形成和发展中的作用。方法将SD大鼠随机分为对照组与模型组,两组大鼠腹部皮下分别注射100%橄榄油和40%CCl4-橄榄油溶液,每周2次,共10周,于第2、6、10周末分批取材,分别抽取各大鼠的血液及切取各实验大鼠的肝脏标本,以ELISA法测定大鼠APN蛋白表达情况,RT-PCR法检测肝中脂联素受体2 mRNA的表达,常规石蜡切片HE染色观察各实验大鼠肝脏形态学改变。结果模型组大鼠APN水平随造模时间延长逐步降低,同时脂联素受体2 mRNA表达同步下降,各时间点模型组与正常对照组比较差异有统计学意义(P<0.05)。结论 APN水平及肝脏脂联素受体表达异常可能在肝纤维化的形成和发展中起一定作用。 Objective To study the significance of expression of serum adiponectin and liver adiponectin receptor 2 mRNA in development of liver fibrosis in experimental rats.Methods SD rats were randomly divided into control group and model group,rats in model group were injected with 100% olive oil and 40% carbon tetrachloride solusion twice every week for 10 weeks.Samples of rat sera and liver tissues were obtained at the end of 2nd,6th,and 10th week.The expression of serum adiponectin was evaluated by ELISA.The expression of hepatic adiponectin receptor 2 mRNA was measured with realtime-polymerase chain reaction.Sections of liver tissue with HE staining were examined for pathological changes.Results In model group,levels of serum adiponectin were gradually decreased,meanwhile,the expression of adiponectin receptor 2 mRNA appeared to be falling down.Significant differences were observed at each time point between rats in model and control groups（P0.05）.Conclusion The variation in expression of adiponectin and its receptor 2 mRNA may be critical in pathogenesis and development of liver fibrosis.

作者沈晟晖袁向亮殷于磊

机构地区上海交通大学医学院附属新华医院急救中心上海交通大学医学院附属新华医院检验科上海复旦大学华东医院病理科

出处《临床和实验医学杂志》 2012年第13期999-1001,共3页 Journal of Clinical and Experimental Medicine

关键词肝纤维化脂联素脂联素受体2 Fibrosis Adiponectin Adiponectin receptor2

分类号 R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献9

1病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62. 被引量：1828
2Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride - induced liver fibrosis in mice lacking adiponectin[ J]. Gastroenterology, 2003,125 (6) : 1796 - 1807.
3Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non - alcoholic steatohcpatitis [ J ]. Gut, 2005,54 ( 1 ) : 117 - 121.
4钱晓武,范竹萍,汪晓红,盛黎,奚志峰,邱德凯.脂联素及其受体2在非酒精性脂肪性肝炎发病过程中的表达[J].世界华人消化杂志,2009,17(19):1925-1930. 被引量：8
5Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects [ J]. Nature, 2003,423(6941) :762 - 769.
6Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease[ J]. J Cardiometab Syndr, 2009,4( 1 ) :44 -49.
7Vuppalanchi R, Marri S, Kolwankar D, et al. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study[ J 1. J Clin Gastroenterol, 2005,39 (3) :237 - 242.
8Gonzdlez CR, Caminos JE, Gallego R, et al. Adiponectin receptor 2 is regulated by nutritional status, leptin and pregnancy in a tissue - specif- ic manner[ J]. Physiol Behav, 2010,99( 1 ) :91 -99.
9Shimizu A, Takamura T, Matsuzawa N, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line [ J ]. Me- tabolism, 2007,56( 11 ) :1478 - 1485.

二级参考文献41

1Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
2Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002; 17: 1136-1143.
3Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
4Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
5Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
6McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255-262.
7Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
8Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 2009; 41: 969-976.
9Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163.
10Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006; 2006: 34295.